![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SYDE2 |
Gene summary for SYDE2 |
![]() |
Gene information | Species | Human | Gene symbol | SYDE2 | Gene ID | 84144 |
Gene name | synapse defective Rho GTPase homolog 2 | |
Gene Alias | SYDE2 | |
Cytomap | 1p22.3 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | Q5VT97 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84144 | SYDE2 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.47e-16 | 5.80e-01 | -0.0166 |
84144 | SYDE2 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.85e-15 | 5.34e-01 | -0.0132 |
84144 | SYDE2 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.57e-15 | 4.77e-01 | -0.013 |
84144 | SYDE2 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 5.13e-12 | 4.88e-01 | -0.0121 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510565 | Lung | IAC | regulation of small GTPase mediated signal transduction | 70/2061 | 302/18723 | 9.44e-10 | 1.87e-07 | 70 |
GO:00430876 | Lung | IAC | regulation of GTPase activity | 67/2061 | 348/18723 | 3.43e-06 | 1.44e-04 | 67 |
GO:00435475 | Lung | IAC | positive regulation of GTPase activity | 48/2061 | 255/18723 | 1.40e-04 | 2.60e-03 | 48 |
GO:00906303 | Lung | IAC | activation of GTPase activity | 22/2061 | 115/18723 | 6.80e-03 | 4.73e-02 | 22 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYDE2 | SNV | Missense_Mutation | c.866N>G | p.Asn289Ser | p.N289S | Q5VT97 | protein_coding | tolerated_low_confidence(0.11) | benign(0.085) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SYDE2 | SNV | Missense_Mutation | c.3531N>C | p.Leu1177Phe | p.L1177F | Q5VT97 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SYDE2 | SNV | Missense_Mutation | novel | c.3289G>A | p.Glu1097Lys | p.E1097K | Q5VT97 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYDE2 | SNV | Missense_Mutation | rs748125795 | c.775N>G | p.Met259Val | p.M259V | Q5VT97 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYDE2 | insertion | Frame_Shift_Ins | novel | c.901_902insAAAAA | p.Leu301GlnfsTer58 | p.L301Qfs*58 | Q5VT97 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SYDE2 | insertion | Frame_Shift_Ins | novel | c.900_901insT | p.Leu301SerfsTer6 | p.L301Sfs*6 | Q5VT97 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SYDE2 | SNV | Missense_Mutation | novel | c.488G>A | p.Gly163Glu | p.G163E | Q5VT97 | protein_coding | deleterious_low_confidence(0) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SYDE2 | SNV | Missense_Mutation | c.731G>T | p.Arg244Ile | p.R244I | Q5VT97 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.548) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SYDE2 | SNV | Missense_Mutation | novel | c.1105N>A | p.Glu369Lys | p.E369K | Q5VT97 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SYDE2 | SNV | Missense_Mutation | c.1161N>C | p.Leu387Phe | p.L387F | Q5VT97 | protein_coding | tolerated_low_confidence(0.21) | possibly_damaging(0.467) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |